IJIRCCE

ISSN(O): 2320-9801

ISSN(P): 2320-9798



International Journal of Innovative Research in Computer and Communication Engineering

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



Impact Factor: 8.771

Volume 13, Issue 3, March 2025

© 2025 IJIRCCE | Volume 13, Issue 3, March 2025| DOI: 10.15680/IJIRCCE.2025.1303045

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

AI for Drug Discovery: A New Era

Dr.R. Bullibabu, B. Kavya, G. Bindu Madhavi, G. Kavya, SK. Sajida

Professor & Head, Department of AIML & DS, Kits Akshar Institute of Technology and Sciences, Guntur, India

Student, Kits Akshar Institute of Technology and Sciences, Guntur, India

ABSTRACT: Artificial intelligence (AI) is revolutionizing drug discovery by accelerating and optimizing various stages of the process. This project explores the application of AI, including machine learning and deep learning, to identify promising drug candidates, predict their efficacy and safety, and design novel molecules. We investigate diverse AI models and algorithms, evaluating their performance on relevant datasets and comparing them to traditional methods. The results demonstrate the potential of AI to significantly reduce the time and cost associated with bringing new drugs to market, ultimately improving human health. This work highlights the transformative impact of AI in pharmaceutical research and paves the way for future advancements in drug development.

KEYWORDS: drug discovery, drug development, drug screening, target identification, gen AI, specific AI models like TensorFlow and scikit-learn.

I. INTRODUCTION

Drug discovery is a lengthy and expensive process that involves identifying potential drug candidates, testing their safety and efficacy, and optimizing them for clinical use. Traditional methods are often time-consuming and resource-intensive, which limits the speed at which new drugs can reach patients. In recent years, Artificial Intelligence (AI) has emerged as a powerful tool to overcome these challenges by automating various stages of drug development.

This project focuses on integrating AI techniques to enhance drug discovery, with a particular emphasis on predictive modeling and data analysis using frameworks like Scikit-learn and Tensor Flow.These AI tools facilitate virtual screening, target identification, and drug repurposing by analyzing large biomedical datasets and predicting molecular properties with high accuracy.

Scikit-learn provides robust machine learning algorithms for classification, regression, and clustering, which help in identifying promising drug candidates and predicting their toxicity and efficacy. TensorFlow, with its deep learning capabilities, enables the development of neural networks for molecular property prediction, making it possible to discover new drug compounds with improved precision.

By combining AI-driven approaches and advanced computational tools, this project aims to create a cost-effective and efficient framework for drug discovery. The proposed system not only accelerates the drug development process but also contributes to reducing failures in later stages of clinical trials, ultimately improving patient outcomes and healthcare innovation.

Scikit-learn provides a suite of machine learning algorithms for classification, regression, clustering, and dimensionality reduction, which are crucial for analyzing molecular properties and identifying potential drug candidates. TensorFlow, with its deep learning capabilities, enables the creation of neural networks that model complex biochemical interactions, facilitating more accurate predictions of drug efficacy and toxicity. The combination of these tools allows for an AI-driven workflow that enhances decision-making and reduces reliance on costly laboratory experiments.

By integrating AI-powered predictive models, this project aims to create an efficient and cost-effective approach to drug discovery. The proposed system not only accelerates the identification of novel drugs but also minimizes failure rates in later stages of development, ultimately improving the success of clinical trials.

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

This project explores the application of AI, including machine learning and deep learning, to identify promising drug candidates, predict their efficacy and safety, and design novel molecules. We investigate diverse AI models and algorithms, evaluating their performance on relevant datasets and comparing them to traditional methods. The results demonstrate the potential of AI to significantly reduce the time and cost associated with bringing new drugs to market, ultimately improving human health. This work highlights the transformative impact of AI in pharmaceutical research and paves the way for future advancements in drug development.

II. LITERATURE SURVEY

The integration of Artificial Intelligence (AI) into drug discovery has transformed pharmaceutical research, enabling faster and more cost-effective drug development. Traditional drug discovery methods rely heavily on trial-and-error approaches, which are time-consuming and expensive. However, AI-driven models, particularly those using machine learning (ML) and deep learning (DL), have demonstrated significant improvements in target identification, virtual screening, and drug repurposing. Several studies have explored the role of AI in drug discovery, highlighting the use of frameworks such as Scikit-learn and TensorFlow for predictive modeling and data analysis. [1]

AI-based methods have proven effective in streamlining the drug discovery process by utilizing large-scale datasets and computational power to predict molecular properties and interactions. According to Ekins et al. (2019), AI has been successfully applied in structure-based drug design, where deep learning models predict the binding affinity of potential drug candidates to specific targets. Additionally, Zhavoronkov et al. (2020) emphasized the role of AI in generative drug design, demonstrating how reinforcement learning and generative adversarial networks (GANs) can generate novel molecular structures with optimized pharmacological properties.[2]

Machine learning techniques, implemented using Scikit-learn, have played a vital role in predicting molecular properties such as solubility, toxicity, and bioavailability. Chen et al. (2018) demonstrated that support vector machines (SVM), random forests (RF), and decision trees are highly effective in classifying molecular compounds based on their biochemical properties. The use of these algorithms in early-stage drug discovery helps researchers prioritize compounds with high therapeutic potential. Additionally, feature selection techniques in Scikit-learn enhance the interpretability of ML models, allowing for better understanding and optimization of molecular structures.[3]

Deep learning models, particularly those implemented using TensorFlow, have shown significant improvements over traditional ML methods in drug discovery. Mayr et al. (2016) reported that convolutional neural networks (CNNs) and recurrent neural networks (RNNs) outperform classical ML algorithms in predicting drug-target interactions. These models can automatically extract meaningful features from molecular representations, improving prediction accuracy. Similarly, Gomes et al. (2021) explored the application of graph neural networks (GNNs) for drug discovery, highlighting their effectiveness in capturing complex molecular structures and interactions. These findings indicate that deep learning offers powerful solutions for improving drug discovery pipelines.[4]

Virtual screening is an essential step in drug discovery, enabling researchers to screen vast chemical libraries to identify potential drug candidates. AI-powered virtual screening techniques have been shown to outperform traditional docking-based approaches. Pereira et al. (2021) demonstrated that ML models trained on molecular descriptors can efficiently predict drug-likeness and binding affinity. Additionally, AI has been instrumental in drug repurposing, where existing drugs are analyzed for new therapeutic applications. Kadioglu et al. (2020) reported that deep learning models trained on biomedical literature and clinical trial data successfully identified repurposed drug candidates for diseases such as COVID-19, reducing the time required for clinical validation.[5]

Despite the advantages of AI in drug discovery, several challenges remain. One major issue is the availability of high-quality labeled datasets, as many drug-related datasets are incomplete or biased. Additionally, the black-box nature of deep learning models makes it difficult to interpret their predictions, limiting their acceptance in regulatory settings. There is a growing need for explainable AI (XAI) techniques that provide transparency in AI-driven decision-making. Moreover, ethical considerations regarding AI-generated molecules and their potential risks must be addressed to ensure responsible AI usage in drug development.[6]

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

The literature review highlights the growing impact of AI in drug discovery, with Scikit-learn and TensorFlow playing key roles in predictive modeling and data-driven analysis. AI-driven methods have demonstrated remarkable efficiency in virtual screening, drug repurposing, and molecular property prediction, reducing the time and cost associated with traditional drug discovery. However, challenges related to data quality, model interpretability, and regulatory compliance must be addressed to ensure the successful integration of AI in pharmaceutical research. Continued advancements in AI and its application in drug discovery have the potential to revolutionize the healthcare industry, leading to faster and more effective treatment development.[7]

III. PROPOSED METHOD

The proposed method leverages Artificial Intelligence (AI), Machine Learning (ML), and Deep Learning (DL) to enhance the drug discovery process. By utilizing Scikit-learn and TensorFlow, this approach focuses on predictive modeling for drug-target interactions, virtual screening, and drug repurposing.

Steps of the Proposed Method

1.Data Collection and Preprocessing: Gather drug-related datasets from sources like PubChem, ChEMBL, DrugBank, and KEGG.Clean and preprocess data by handling missing values, normalizing molecular properties, and removing duplicate records.Convert chemical compounds into structured formats (SMILES, molecular fingerprints) to facilitate ML model training.

2.Feature Selection and Data Preparation: Extract relevant molecular descriptors using RDKit for numerical representation of chemical properties.Select the most informative features using Principal Component Analysis (PCA), Recursive Feature Elimination (RFE), or Mutual Information Gain.Split the dataset into training (80%) and testing (20%) sets to ensure model reliability.

3.Virtual Screening & Drug Repurposing: Apply trained ML and DL models to screen chemical libraries and predict drug-likeness.Identify potential candidates for drug repurposing by analyzing known drug interactions with new targets.

4.Model Validation & Performance Analysis: Validate models using cross-validation and external benchmark datasets to assess generalizability.Compare results against existing benchmark studies to ensure robustness.

5.Deployment & Interpretation: Develop a user-friendly interface (e.g., web-based or API) for researchers to input molecular data and receive predictions.Implement Explainable AI (XAI) techniques to interpret model decisions for better trust and adoption in drug discovery.



Fig. Block diagram

Proposed system modules

1. This module gathers drug-related datasets from sources like PubChem, ChEMBL, and DrugBank, cleans the data, removes duplicates, and converts molecular structures into machine-readable formats such as SMILES and fingerprints.
2. Key molecular descriptors are extracted using RDKit, and relevant features are selected using PCA, RFE, or Mutual Information Gain. The dataset is then split into training and testing sets to ensure robust model evaluation.
3. AI models are used to screen large chemical libraries and predict drug-likeness, toxicity, and bioactivity, identifying potential candidates for new or repurposed drugs based on similarity analysis and binding affinity predictions.
4. A web-based or API interface is developed for users to input molecular structures and receive AI-driven predictions with Explainable AI (XAI) techniques for transparency.

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

Advantages of the Proposed System

- AI accelerates the process by generating novel molecules quickly.
- Reduces the need for expensive lab experiments and manual screening.
- Generates unique and diverse chemical structures efficiently.
- AI refines molecules based on drug-likeness and bioactivity.
- Can generate unlimited drug candidates, enhancing research possibilities.

IV. RESULTS







© 2025 IJIRCCE | Volume 13, Issue 3, March 2025| DOI: 10.15680/IJIRCCE.2025.1303045

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



Fig: Code of the Project



Fig: Loading datasets



Fig. Output for the project

V.CONCLUSION

The application of Generative AI in molecular design presents a paradigm shift in drug discovery, offering an automated, scalable, and data-driven approach to identifying novel compounds. The fine-tuned GPT-2 model effectively learns the structural patterns of bioactive molecules, allowing the generation of chemically valid and diverse SMILES sequences. This AI-driven framework not only reduces the time and cost associated with early-stage drug discovery but also enables rapid screening and optimization of molecular candidates. Future work will explore integration with biochemical validation techniques, ensuring practical applicability in real-world pharmaceutical research.

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 8.771| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

Our study highlights the efficiency of AI-powered de novo molecular design, utilizing Generative AI models to explore vast chemical spaces with unprecedented speed. By training GPT-2 on molecular datasets, we have demonstrated its ability to generate novel and structurally valid drug-like molecules, potentially accelerating lead identification.

The proposed approach reduces dependency on exhaustive experimental synthesis and screening, making drug discovery more accessible and cost-effective. Further research will focus on refining molecular generation, improving bioactivity predictions, and integrating AI-driven drug design with real-world validation techniques.

REFERENCES

1. **Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., et al. (2019).** Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnology*, 37, 1038–1040. https://doi.org/10.1038/s41587-019-0224-x
2. **Sanchez-Lengeling, B., & Aspuru-Guzik, A. (2018).** Inverse molecular design using machine learning: Generative models for matter engineering. *Science*, 361(6400), 360–365. https://doi.org/10.1126/science.aat2663
3. **Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019).** Deep learning for molecular design—a review of the state of the art. *Molecular Systems Design & Engineering*, 4(4), 828–849. https://doi.org/10.1039/C9ME00039A
4. **Zhavoronkov, A. (2018).** Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. *Molecular Pharmaceutics*, 15(10), 4311–4313. https://doi.org/10.1021/acs.molpharmaceut.8b00930
5. **Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019).** GuacaMol: Benchmarking models for de novo molecular design. *Journal of Chemical Information and Modeling*, 59(3), 1096–1108. https://doi.org/10.1021/acs.jcim.8b00839
6. **Olivecrona, M., Blaschke, T., Engkvist, O., & Chen, H. (2017).** Molecular de novo design through deep reinforcement learning. *Journal of Cheminformatics*, 9, 48. https://doi.org/10.1186/s13321-017-0235-x
7. **Schneider, G. (2018).** Automating drug discovery. *Nature Reviews Drug Discovery*, 17, 97–113. https://doi.org/10.1038/nrd.2017.232

INTERNATIONAL STANDARD SERIAL NUMBER INDIA

INNO SPACE SJIF Scientific Journal Impact Factor

doi crossref

निस्केयर NISCAIR

INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN COMPUTER & COMMUNICATION ENGINEERING

9940 572 462 6381 907 438 ijircce@gmail.com

www.ijircce.com

Scan to save the contact details